| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| NSABP FB-12 | This is a study for patients diagnosed with Her2 negative breast cancer. It is looking at the effectiveness and safety of doxorubicin plus cyclophosphamide followed by weekly paclitaxel plus trastuzumab and pertuzumab before surgery. | Cancer | Breast |
| S1608 | This study is for patients who have failed to achieve a complete remission or have relapsed within 2 years after completing treatment. You must have been diagnosed with follicular lymphoma grade 1, 2, or 3. | Cancer | Follicular Lymphoma |
| S1703 | This study is looking at overall survival or patients monitored with serum tumor markers veruss usual care. You must be diagnosed with metastatic hormone receptor positive breast cancer. | Cancer | Metastatic Breast |
| A151216 (ALCHEMIST) | The purpose of this study is to send tissue for screening of mutations to find targeted therapy for your cancer. You must be diagnosed with stage 1B, stage 2 or stage 3A resectable or completely resected non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| Agendia FLEX | The purpose of this study is to create a large population based database to identify new gene associations in breast cancer. You must be diagnosed with stage 1, 2 or 3 breast cancer. A report is created that looks at the risk of your cancer spreading over the next 10 years. | Cancer | Breast |
| EA6141 | The purpose of this study is to compare the effectiveness of Nivolumab, Ipilimumab and Sargramostim vs Nivolumab and Ipilmumab. You must be diagnosed with unresectable stage 3 or stage 4 melanoma. | Cancer | Melanoma |
| TAPUR | The purpose of this study is find targeted treatment for patients with advanced cancer that has a actionable genomic variant revealed by genomic testing. Tissue from your cancer must be sent for genomic screening. You must have an advanced solid tumor, mulitple myeloma or B cell non-Hodgkin lymphona for which standard treatment options are no longer available. | Cancer | All tumor types |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.